{"pmid":32297540,"title":"Association between platelet parameters and mortality in coronavirus disease 2019: Retrospective cohort study.","text":["Association between platelet parameters and mortality in coronavirus disease 2019: Retrospective cohort study.","Background: Thrombocytopenia has been implicated in patients infected with severe acute respiratory syndrome coronavirus 2, while the association of platelet count and changes with subsequent mortality remains unclear.Methods: The clinical and laboratory data of 383 patients with the definite outcome by March 1, 2020 in the Central Hospital of Wuhan were reviewed. The association between platelet parameters and mortality risk was estimated by utilizing Cox proportional hazard regression models.Results: Among the 383 patients, 334 (87.2%) were discharged and survived, and 49 (12.8%) died. Thrombocytopenia at admission was associated with mortality of almost three times as high as that for those without thrombocytopenia (P < 0.05). Cox regression analyses revealed that platelet count was an independent risk factor associated with in-hospital mortality in a dose-dependent manner. An increment of per 50 x 10(9)/L in platelets was associated with a 40% decrease in mortality (hazard ratio: 0.60, 95%CI: 0.43, 0.84). Dynamic changes of platelets were also closely related to death during hospitalization.Conclusions: Baseline platelet levels and changes were associated with subsequent mortality. Monitoring platelets during hospitalization may be important in the prognosis of patients with coronavirus disease in 2019.","Platelets","Liu, Yanli","Sun, Wenwu","Guo, Yanan","Chen, Liangkai","Zhang, Lijuan","Zhao, Su","Long, Ding","Yu, Li","32297540"],"abstract":["Background: Thrombocytopenia has been implicated in patients infected with severe acute respiratory syndrome coronavirus 2, while the association of platelet count and changes with subsequent mortality remains unclear.Methods: The clinical and laboratory data of 383 patients with the definite outcome by March 1, 2020 in the Central Hospital of Wuhan were reviewed. The association between platelet parameters and mortality risk was estimated by utilizing Cox proportional hazard regression models.Results: Among the 383 patients, 334 (87.2%) were discharged and survived, and 49 (12.8%) died. Thrombocytopenia at admission was associated with mortality of almost three times as high as that for those without thrombocytopenia (P < 0.05). Cox regression analyses revealed that platelet count was an independent risk factor associated with in-hospital mortality in a dose-dependent manner. An increment of per 50 x 10(9)/L in platelets was associated with a 40% decrease in mortality (hazard ratio: 0.60, 95%CI: 0.43, 0.84). Dynamic changes of platelets were also closely related to death during hospitalization.Conclusions: Baseline platelet levels and changes were associated with subsequent mortality. Monitoring platelets during hospitalization may be important in the prognosis of patients with coronavirus disease in 2019."],"journal":"Platelets","authors":["Liu, Yanli","Sun, Wenwu","Guo, Yanan","Chen, Liangkai","Zhang, Lijuan","Zhao, Su","Long, Ding","Yu, Li"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32297540","week":"202016|Apr 13 - Apr 19","doi":"10.1080/09537104.2020.1754383","keywords":["Cohort study","coronavirus disease 2019","mortality","platelet count","severe acute respiratory syndrome coronavirus 2"],"source":"PubMed","weight":0,"locations":["Thrombocytopenia","Wuhan","Thrombocytopenia"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664266651311276033,"score":8.233237,"similar":[{"pmid":32302435,"title":"Thrombocytopenia and Its Association with Mortality in Patients with COVID-19.","text":["Thrombocytopenia and Its Association with Mortality in Patients with COVID-19.","BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes novel coronavirus disease 2019 (COVID-19), is spreading rapidly around the world. Thrombocytopenia in patients with COVID-19 has not been fully studied. OBJECTIVE: To describe thrombocytopenia in patients with COVID-19. METHODS: For each of 1476 consecutive patients with COVID-19 from Jinyintan Hospital, Wuhan, China, nadir platelet count during hospitalization was retrospectively collected and categorized into (0, 50], (50, 100], (100 - 150] or (150 - ) group after taking the unit (x 10(9/L) ) away from the report of nadir platelet count. Nadir platelet counts and in-hospital mortality were analyzed. RESULTS: Among all patients, 238 (16.1%) patients deceased and 306 (20.7%) had thrombocytopenia. Compared with survivors, non-survivors were older, were more likely to have thrombocytopenia and had lower nadir platelet counts. The in-hospital mortality was 92.1%, 61.2%, 17.5% and 4.7% for (0, 50], (50, 100], (100 - 150] and (150 - ) group, respectively. With (150 - ) as the reference, nadir platelet counts of (100 - 150], (50, 100] and (0, 50] group had a relative risk of 3.42 (95% CI 2.36 - 4.96), 9.99 (95% CI 7.16 - 13.94) and 13.68 (95% CI 9.89 - 18.92), respectively. CONCLUSIONS: Thrombocytopenia is common in patients with COVID-19, and it is associated with increased risk of in-hospital mortality. The lower the platelet count is, the higher the mortality becomes.","J Thromb Haemost","Yang, Xiaobo","Yang, Qingyu","Wang, Yaxin","Wu, Yongran","Xu, Jiqian","Yu, Yuan","Shang, You","32302435"],"abstract":["BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes novel coronavirus disease 2019 (COVID-19), is spreading rapidly around the world. Thrombocytopenia in patients with COVID-19 has not been fully studied. OBJECTIVE: To describe thrombocytopenia in patients with COVID-19. METHODS: For each of 1476 consecutive patients with COVID-19 from Jinyintan Hospital, Wuhan, China, nadir platelet count during hospitalization was retrospectively collected and categorized into (0, 50], (50, 100], (100 - 150] or (150 - ) group after taking the unit (x 10(9/L) ) away from the report of nadir platelet count. Nadir platelet counts and in-hospital mortality were analyzed. RESULTS: Among all patients, 238 (16.1%) patients deceased and 306 (20.7%) had thrombocytopenia. Compared with survivors, non-survivors were older, were more likely to have thrombocytopenia and had lower nadir platelet counts. The in-hospital mortality was 92.1%, 61.2%, 17.5% and 4.7% for (0, 50], (50, 100], (100 - 150] and (150 - ) group, respectively. With (150 - ) as the reference, nadir platelet counts of (100 - 150], (50, 100] and (0, 50] group had a relative risk of 3.42 (95% CI 2.36 - 4.96), 9.99 (95% CI 7.16 - 13.94) and 13.68 (95% CI 9.89 - 18.92), respectively. CONCLUSIONS: Thrombocytopenia is common in patients with COVID-19, and it is associated with increased risk of in-hospital mortality. The lower the platelet count is, the higher the mortality becomes."],"journal":"J Thromb Haemost","authors":["Yang, Xiaobo","Yang, Qingyu","Wang, Yaxin","Wu, Yongran","Xu, Jiqian","Yu, Yuan","Shang, You"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32302435","week":"202016|Apr 13 - Apr 19","doi":"10.1111/jth.14848","keywords":["covid-19","sars-cov-2","generalized linear model","mortality","thrombocytopenia"],"source":"PubMed","topics":["NONE","Diagnosis"],"weight":1,"locations":["Thrombocytopenia","Jinyintan Hospital","Wuhan","China","thrombocytopenia","Thrombocytopenia","Thrombocytopenia"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664357978563674114,"score":453.66345},{"pmid":32178975,"pmcid":"PMC7102663","title":"Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis.","text":["Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis.","BACKGROUND: Coronavirus disease 2019 (COVID-19) is a novel infectious disease with lack of established laboratory markers available to evaluate illness severity. In this study, we investigate whether platelet count could differentiate between COVID-19 patients with or without severe disease. Additionally, we evaluate if thrombocytopenia is associated with severe COVID-19. METHODS: An electronic search in Medline, Scopus and Web of Science was performed to identify studies reporting data on platelet count in COVID-19 patients. A meta-analysis was performed, with calculation of weighted mean difference (WMD) of platelet number in COVID-19 patients with or without severe disease and odds ratio (OR) of thrombocytopenia for severe form of COVID-19. RESULTS: Nine studies with 1779 COVID-19 patients, 399 (22.4%) with severe disease, were included in the meta-analysis. The pooled analysis revealed that platelet count was significantly lower in patients with more severe COVID-19 (WMD -31 x 10(9)/L; 95% CI, from -35 to -29 x 10(9)/L). A subgroup analysis comparing patients by survival, found an even lower platelet count was observed with mortality (WMD, -48 x 10(9)/L; 95% CI, -57 to -39 x 10(9)/L. In the four studies (n = 1427) which reported data on rate of thrombocytopenia, a low platelet count was associated with over fivefold enhanced risk of severe COVID-19 (OR, 5.1; 95% CI, 1.8-14.6). CONCLUSIONS: Low platelet count is associated with increased risk of severe disease and mortality in patients with COVID-19, and thus should serve as clinical indicator of worsening illness during hospitalization.","Clin Chim Acta","Lippi, Giuseppe","Plebani, Mario","Henry, Brandon Michael","32178975"],"abstract":["BACKGROUND: Coronavirus disease 2019 (COVID-19) is a novel infectious disease with lack of established laboratory markers available to evaluate illness severity. In this study, we investigate whether platelet count could differentiate between COVID-19 patients with or without severe disease. Additionally, we evaluate if thrombocytopenia is associated with severe COVID-19. METHODS: An electronic search in Medline, Scopus and Web of Science was performed to identify studies reporting data on platelet count in COVID-19 patients. A meta-analysis was performed, with calculation of weighted mean difference (WMD) of platelet number in COVID-19 patients with or without severe disease and odds ratio (OR) of thrombocytopenia for severe form of COVID-19. RESULTS: Nine studies with 1779 COVID-19 patients, 399 (22.4%) with severe disease, were included in the meta-analysis. The pooled analysis revealed that platelet count was significantly lower in patients with more severe COVID-19 (WMD -31 x 10(9)/L; 95% CI, from -35 to -29 x 10(9)/L). A subgroup analysis comparing patients by survival, found an even lower platelet count was observed with mortality (WMD, -48 x 10(9)/L; 95% CI, -57 to -39 x 10(9)/L. In the four studies (n = 1427) which reported data on rate of thrombocytopenia, a low platelet count was associated with over fivefold enhanced risk of severe COVID-19 (OR, 5.1; 95% CI, 1.8-14.6). CONCLUSIONS: Low platelet count is associated with increased risk of severe disease and mortality in patients with COVID-19, and thus should serve as clinical indicator of worsening illness during hospitalization."],"journal":"Clin Chim Acta","authors":["Lippi, Giuseppe","Plebani, Mario","Henry, Brandon Michael"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32178975","week":"202012|Mar 16 - Mar 22","doi":"10.1016/j.cca.2020.03.022","keywords":["Coronavirus, COVID-19","Platelets","Thrombocytopenia"],"source":"PubMed","locations":["Medline","thrombocytopenia","Scopus","Thrombocytopenia"],"topics":["Diagnosis"],"weight":1,"_version_":1663352133874876416,"score":413.1164},{"pmid":32181903,"title":"Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19.","text":["Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19.","Since December 2019, novel coronavirus infected pneumonia emerged in Wuhan city and rapidly spread throughout China. In severe novel coronavirus pneumonia cases, the number of platelets, their dynamic changes during the treatment, platelet-to-lymphocyte ratio (PLR) were a concern. We sought to describe the platelet feature of these cases. Single-center case series of the 30 hospitalized patients with confirmed coronavirus disease (COVID)-19 in Huizhou municipal central hospital from January 2020 to February 2020 were retrospectively analyzed. Demographic, clinical, blood routine results, other laboratory results, and treatment data were collected and analyzed. Outcomes of severe patients and nonsevere patients were compared. Univariate analysis showed that: age, platelet peaks, and PLR at peak platelet were the influencing factors in severe patients, multivariate analysis showed that the PLR value at peak platelet during treatment was an independent influencing factor in severe patients. The average hospitalization day of patients with platelet peaks during treatment was longer than those without platelet peaks (P < .05). The average age of patients with platelet peaks during treatment was older than those without platelet peaks (P < .05). The patients with significantly elevated platelets during treatment had longer average hospitalization days. And the higher PLR of patients during treatment had longer average hospitalization days. Single-center case series of the 30 hospitalized patients with confirmed COVID-19 in Huizhou Municipal Central Hospital, presumed that the number of platelets and their dynamic changes during the treatment may have a suggestion on the severity and prognosis of the disease. The patient with markedly elevated platelets and longer average hospitalization days may be related to the cytokine storm. The PLR of patients means the degree of cytokine storm, which might provide a new indicator in the monitoring in patients with COVID-19.","J Med Virol","Qu, Rong","Ling, Yun","Zhang, Yi-Hui-Zhi","Wei, Li-Ya","Chen, Xiao","Li, Xu-Mian","Liu, Xuan-Yong","Liu, Han-Mian","Guo, Zhi","Ren, Hua","Wang, Qiang","32181903"],"abstract":["Since December 2019, novel coronavirus infected pneumonia emerged in Wuhan city and rapidly spread throughout China. In severe novel coronavirus pneumonia cases, the number of platelets, their dynamic changes during the treatment, platelet-to-lymphocyte ratio (PLR) were a concern. We sought to describe the platelet feature of these cases. Single-center case series of the 30 hospitalized patients with confirmed coronavirus disease (COVID)-19 in Huizhou municipal central hospital from January 2020 to February 2020 were retrospectively analyzed. Demographic, clinical, blood routine results, other laboratory results, and treatment data were collected and analyzed. Outcomes of severe patients and nonsevere patients were compared. Univariate analysis showed that: age, platelet peaks, and PLR at peak platelet were the influencing factors in severe patients, multivariate analysis showed that the PLR value at peak platelet during treatment was an independent influencing factor in severe patients. The average hospitalization day of patients with platelet peaks during treatment was longer than those without platelet peaks (P < .05). The average age of patients with platelet peaks during treatment was older than those without platelet peaks (P < .05). The patients with significantly elevated platelets during treatment had longer average hospitalization days. And the higher PLR of patients during treatment had longer average hospitalization days. Single-center case series of the 30 hospitalized patients with confirmed COVID-19 in Huizhou Municipal Central Hospital, presumed that the number of platelets and their dynamic changes during the treatment may have a suggestion on the severity and prognosis of the disease. The patient with markedly elevated platelets and longer average hospitalization days may be related to the cytokine storm. The PLR of patients means the degree of cytokine storm, which might provide a new indicator in the monitoring in patients with COVID-19."],"journal":"J Med Virol","authors":["Qu, Rong","Ling, Yun","Zhang, Yi-Hui-Zhi","Wei, Li-Ya","Chen, Xiao","Li, Xu-Mian","Liu, Xuan-Yong","Liu, Han-Mian","Guo, Zhi","Ren, Hua","Wang, Qiang"],"date":"2020-03-18T11:00:00Z","year":2020,"_id":"32181903","week":"202012|Mar 16 - Mar 22","doi":"10.1002/jmv.25767","keywords":["coronavirus disease","cytokine storm","platelet value","platelet-to-lymphocyte ratio","risk factor"],"source":"PubMed","locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"weight":0,"_version_":1663352133836079104,"score":298.74234},{"pmid":32247631,"title":"Kidney disease is associated with in-hospital death of patients with COVID-19.","text":["Kidney disease is associated with in-hospital death of patients with COVID-19.","In December 2019, a coronavirus 2019 (COVID-19) disease outbreak occurred in Wuhan, Hubei Province, China, and rapidly spread to other areas worldwide. Although diffuse alveolar damage and acute respiratory failure were the main features, the involvement of other organs needs to be explored. Since information on kidney disease in patients with COVID-19 is limited, we determined the prevalence of acute kidney injury (AKI) in patients with COVID-19. Further, we evaluated the association between markers of abnormal kidney function and death in patients with COVID-19. This was a prospective cohort study of 701 patients with COVID-19 admitted in a tertiary teaching hospital that also encompassed three affiliates following this major outbreak in Wuhan in 2020 of whom 113 (16.1%) died in hospital. Median age of the patients was 63 years (interquartile range, 50-71), including 367 men and 334 women. On admission, 43.9% of patients had proteinuria and 26.7% had hematuria. The prevalence of elevated serum creatinine, elevated blood urea nitrogen and estimated glomerular filtration under 60 ml/min/1.73m(2) were 14.4, 13.1 and 13.1%, respectively. During the study period, AKI occurred in 5.1% patients. Kaplan-Meier analysis demonstrated that patients with kidney disease had a significantly higher risk for in-hospital death. Cox proportional hazard regression confirmed that elevated baseline serum creatinine (hazard ratio: 2.10, 95% confidence interval: 1.36-3.26), elevated baseline blood urea nitrogen (3.97, 2.57-6.14), AKI stage 1 (1.90, 0.76-4.76), stage 2 (3.51, 1.49-8.26), stage 3 (4.38, 2.31-8.31), proteinuria 1+ (1.80, 0.81-4.00), 2+ approximately 3+ (4.84, 2.00-11.70), and hematuria 1+ (2.99, 1.39-6.42), 2+ approximately 3+ (5.56,2.58- 12.01) were independent risk factors for in-hospital death after adjusting for age, sex, disease severity, comorbidity and leukocyte count. Thus, our findings show the prevalence of kidney disease on admission and the development of AKI during hospitalization in patients with COVID-19 is high and is associated with in-hospital mortality. Hence, clinicians should increase their awareness of kidney disease in patients with severe COVID-19.","Kidney Int","Cheng, Yichun","Luo, Ran","Wang, Kun","Zhang, Meng","Wang, Zhixiang","Dong, Lei","Li, Junhua","Yao, Ying","Ge, Shuwang","Xu, Gang","32247631"],"abstract":["In December 2019, a coronavirus 2019 (COVID-19) disease outbreak occurred in Wuhan, Hubei Province, China, and rapidly spread to other areas worldwide. Although diffuse alveolar damage and acute respiratory failure were the main features, the involvement of other organs needs to be explored. Since information on kidney disease in patients with COVID-19 is limited, we determined the prevalence of acute kidney injury (AKI) in patients with COVID-19. Further, we evaluated the association between markers of abnormal kidney function and death in patients with COVID-19. This was a prospective cohort study of 701 patients with COVID-19 admitted in a tertiary teaching hospital that also encompassed three affiliates following this major outbreak in Wuhan in 2020 of whom 113 (16.1%) died in hospital. Median age of the patients was 63 years (interquartile range, 50-71), including 367 men and 334 women. On admission, 43.9% of patients had proteinuria and 26.7% had hematuria. The prevalence of elevated serum creatinine, elevated blood urea nitrogen and estimated glomerular filtration under 60 ml/min/1.73m(2) were 14.4, 13.1 and 13.1%, respectively. During the study period, AKI occurred in 5.1% patients. Kaplan-Meier analysis demonstrated that patients with kidney disease had a significantly higher risk for in-hospital death. Cox proportional hazard regression confirmed that elevated baseline serum creatinine (hazard ratio: 2.10, 95% confidence interval: 1.36-3.26), elevated baseline blood urea nitrogen (3.97, 2.57-6.14), AKI stage 1 (1.90, 0.76-4.76), stage 2 (3.51, 1.49-8.26), stage 3 (4.38, 2.31-8.31), proteinuria 1+ (1.80, 0.81-4.00), 2+ approximately 3+ (4.84, 2.00-11.70), and hematuria 1+ (2.99, 1.39-6.42), 2+ approximately 3+ (5.56,2.58- 12.01) were independent risk factors for in-hospital death after adjusting for age, sex, disease severity, comorbidity and leukocyte count. Thus, our findings show the prevalence of kidney disease on admission and the development of AKI during hospitalization in patients with COVID-19 is high and is associated with in-hospital mortality. Hence, clinicians should increase their awareness of kidney disease in patients with severe COVID-19."],"journal":"Kidney Int","authors":["Cheng, Yichun","Luo, Ran","Wang, Kun","Zhang, Meng","Wang, Zhixiang","Dong, Lei","Li, Junhua","Yao, Ying","Ge, Shuwang","Xu, Gang"],"date":"2020-04-06T11:00:00Z","year":2020,"_id":"32247631","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.kint.2020.03.005","keywords":["COVID-19","acute kidney injury","in-hospital death","kidney disease","pneumonia"],"source":"PubMed","locations":["China","Wuhan","Hubei"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"e_drugs":["Creatinine","Nitrogen","Urea"],"_version_":1663352136184889344,"score":237.66914},{"pmid":32286245,"title":"Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis.","text":["Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis.","Background As coronavirus disease 2019 (COVID-19) pandemic rages on, there is urgent need for identification of clinical and laboratory predictors for progression towards severe and fatal forms of this illness. In this study we aimed to evaluate the discriminative ability of hematologic, biochemical and immunologic biomarkers in patients with and without the severe or fatal forms of COVID-19. Methods An electronic search in Medline (PubMed interface), Scopus, Web of Science and China National Knowledge Infrastructure (CNKI) was performed, to identify studies reporting on laboratory abnormalities in patients with COVID-19. Studies were divided into two separate cohorts for analysis: severity (severe vs. non-severe and mortality, i.e. non-survivors vs. survivors). Data was pooled into a meta-analysis to estimate weighted mean difference (WMD) with 95% confidence interval (95% CI) for each laboratory parameter. Results A total number of 21 studies was included, totaling 3377 patients and 33 laboratory parameters. While 18 studies (n = 2984) compared laboratory findings between patients with severe and non-severe COVID-19, the other three (n = 393) compared survivors and non-survivors of the disease and were thus analyzed separately. Patients with severe and fatal disease had significantly increased white blood cell (WBC) count, and decreased lymphocyte and platelet counts compared to non-severe disease and survivors. Biomarkers of inflammation, cardiac and muscle injury, liver and kidney function and coagulation measures were also significantly elevated in patients with both severe and fatal COVID-19. Interleukins 6 (IL-6) and 10 (IL-10) and serum ferritin were strong discriminators for severe disease. Conclusions Several biomarkers which may potentially aid in risk stratification models for predicting severe and fatal COVID-19 were identified. In hospitalized patients with respiratory distress, we recommend clinicians closely monitor WBC count, lymphocyte count, platelet count, IL-6 and serum ferritin as markers for potential progression to critical illness.","Clin Chem Lab Med","Henry, Brandon Michael","de Oliveira, Maria Helena Santos","Benoit, Stefanie","Plebani, Mario","Lippi, Giuseppe","32286245"],"abstract":["Background As coronavirus disease 2019 (COVID-19) pandemic rages on, there is urgent need for identification of clinical and laboratory predictors for progression towards severe and fatal forms of this illness. In this study we aimed to evaluate the discriminative ability of hematologic, biochemical and immunologic biomarkers in patients with and without the severe or fatal forms of COVID-19. Methods An electronic search in Medline (PubMed interface), Scopus, Web of Science and China National Knowledge Infrastructure (CNKI) was performed, to identify studies reporting on laboratory abnormalities in patients with COVID-19. Studies were divided into two separate cohorts for analysis: severity (severe vs. non-severe and mortality, i.e. non-survivors vs. survivors). Data was pooled into a meta-analysis to estimate weighted mean difference (WMD) with 95% confidence interval (95% CI) for each laboratory parameter. Results A total number of 21 studies was included, totaling 3377 patients and 33 laboratory parameters. While 18 studies (n = 2984) compared laboratory findings between patients with severe and non-severe COVID-19, the other three (n = 393) compared survivors and non-survivors of the disease and were thus analyzed separately. Patients with severe and fatal disease had significantly increased white blood cell (WBC) count, and decreased lymphocyte and platelet counts compared to non-severe disease and survivors. Biomarkers of inflammation, cardiac and muscle injury, liver and kidney function and coagulation measures were also significantly elevated in patients with both severe and fatal COVID-19. Interleukins 6 (IL-6) and 10 (IL-10) and serum ferritin were strong discriminators for severe disease. Conclusions Several biomarkers which may potentially aid in risk stratification models for predicting severe and fatal COVID-19 were identified. In hospitalized patients with respiratory distress, we recommend clinicians closely monitor WBC count, lymphocyte count, platelet count, IL-6 and serum ferritin as markers for potential progression to critical illness."],"journal":"Clin Chem Lab Med","authors":["Henry, Brandon Michael","de Oliveira, Maria Helena Santos","Benoit, Stefanie","Plebani, Mario","Lippi, Giuseppe"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32286245","week":"202016|Apr 13 - Apr 19","doi":"10.1515/cclm-2020-0369","keywords":["COVID-19","clinical chemistry","coronavirus"],"source":"PubMed","topics":["Diagnosis"],"weight":1,"locations":["Medline","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664071627193712640,"score":237.37239}]}